Changzhou, China and Misgav, Israel, 17th December 2021 – China-based Waston Medical, one of the top players in China’s medical device industry, The China-Israel Changzhou Innovation Park (“CIP”), a binational governmental initiative that provides a unique platform for Israeli industrial companies seeking to enter the Chinese market, and Israel-headquartered Trendlines Innovation Labs, the innovation and R&D arm of The Trendlines Group, announced the signing of a collaborative technology innovation and development agreement in the field of intracorporeal anastomosis.
Changzhou Waston Medical Appliance Co., Ltd. was established in 2002 and is located in Wujin High-tech Industrial Development Zone, Jiangsu Province. It covers an area of 100,000 square meters. It has standard workshops of 50,000 square meters, purification workshops of 8,000 square meters, and R&D workshops of 3,000 square meters. Testing equipment; production, R&D, and management personnel who have obtained professional technical titles account for more than 40% of the total.
Relying on the technical support and close cooperation of Peking Union Medical College Hospital, Beijing Military Region General Hospital, Southern Medical University, Soochow University, Changzhou Science and Education City and other institutions, there are 35 invention patents and 98 utility model patents. The company has five categories of products including orthopedic implants, surgical staplers, cardiothoracic surgery implants, surgical instruments and medical three-dimensional printers.
Trendlines Innovation Labs is an innovation partner, inventing and investing with medical device companies around the world. Trendlines Innovation Labs brings a wealth of expertise in invention and development of breakthrough medical products with a focus on innovation. Trendlines Innovation Labs’ strength is its ability to invent new solutions and products with speed and focus to meet critical unmet needs and improve the human condition.
The collaboration agreement builds on the strengths of each party by joining forces around technology innovation and development in the field of intracorporeal anastomosis, with a focus on bringing new solutions to the healthcare industry in China and beyond.
Nir Goldenberg, CEO of Trendlines Innovation Labs, added, “Our collaboration with Waston Medical enables us to develop innovative medical products for the Chinese market while leveraging on Waston’s in-depth knowledge of market needs, our agile development capabilities, and our close long-term partnership with CIP which provides further support for entering the Chinese market”.
About Waston Medical
WASTON operates in strict adherence with the ISO13485:2003 (YY/T0287-2003) International Quality System. As a renowned Chinese manufacturer, we strive to uphold the integrity of our conduct. All products are fully certified by CE. Our surgical stapler was among the first to be approved by the American standard FDA510 (K). Our accessories and equipment are now available in regions such as South America, the Middle East, Southeast Asia, Eastern Europe, and North Africa. We have export destinations in countries including America, France, Italy, Germany, Switzerland, the UK, etc. Cooperative business relations with well-known Occidental companies have allowed us to either match or surpass the performance of analogous products on the international market.
The China-Israel Changzhou Innovation Park Initiative (CIP) is a binational governmental initiative supporting Israeli companies entering the Chinese market. The initiative provides companies the opportunity to establish operations in the Changzhou Park in Jiangsu Province and receive incentives and the support of the Park’s facilities and staff.
About The Trendlines Group Ltd.
Trendlines invests in and incubates innovation-based medical and agrifood technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).
Trendlines Innovation Labs, Nir Goldenberg, CEO, email@example.com, T +972.72.260.7000